Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival

Purpose: To assess the kinetics of molecular response to Imatinib Mesylate (IM) therapy in predicting progression free survival (PFS), sustained hematological, and cytogenetic responses in CPCML. Methods: Ninety five newly diagnosed CPCML Egyptian patients were treated with IM 400 mg daily dose. Cyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmoud, Hossam K, El Nahas, Yasser, Abdel Moaty, Mohamad, Abdel Fattah, Raafat, El Emary, Mohamad, El Metnawy, Wafaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Master Publishing Group 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614782/
https://www.ncbi.nlm.nih.gov/pubmed/23675141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614782/
https://www.ncbi.nlm.nih.gov/pubmed/23675141

Ejemplares similares